# TargeGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/targegen

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.targegen.com
- Total disclosed funding: $110M
- Latest round: Series D (May 7, 2007)
- Investors on record: 13

## About

TargeGen, Inc. focuses on providing innovative digital branding solutions, including domain name sales and associated services, targeting startups and established businesses across various sectors.TargeGen, Inc. was founded in 2002 and is headquartered in San Diego, US. The company specializes in digital branding solutions, including domain name sales. In June 2010, TargeGen was acquired by Sanofi-Aventis for USD 75 mn, marking a significant transition in its business operations.TargeGen.com offers a comprehensive suite of products and services primarily focused on domain name sales, branding, and associated digital services aimed at startups and established businesses. The company's core offerings include a marketplace featuring over 300,000 brandable domain names, including modern extensions such as .ai, .io, and .xyz, catering to clients looking to establish a strong online presence. In addition to domain sales, TargeGen provides trademark validation and filing services, AI-powered branding solutions, and name generation tools, all designed to facilitate the naming process for businesses across various sectors, including technology, marketing, and project management. The platform serves a global client base, enabling entrepreneurs and businesses from diverse geographical markets to access premium domains and branding resources tailored to their specific needs.TargeGen.com generates revenue through direct sales of domain names, branding services, and associated tools. The company operates on a straightforward transaction structure, where clients purchase domains and related services through a one-time payment model. The pricing for domains such as TargeGen.com is set at USD 4,888, reflecting the premium nature of the offerings. In addition to one-time purchases, TargeGen may offer payment plans that allow clients to make smaller monthly payments, which also contribute to revenue streams. The company's services may encompass additional fees for trademark services, surveys, and AI-powered branding tools, further enhancing its business model and providing clients with a comprehensive digital branding solution.Following the acquisition in June 2010, TargeGen aims to leverage its resources for expanding its product offerings and entering new markets. The company is currently designing new digital branding tools and services intended for release in the upcoming year, focusing on enhancing user experience. TargeGen plans to expand its operations into emerging markets in Asia and Europe by the end of 2023, utilizing the funding from its recent acquisition to support these strategic initiatives.

## Funding rounds

- Series D, May 7, 2007, $40M — Enterprise Partners Venture Capital, Forward Ventures, VantagePoint Capital, William Blair Capital Partners, Pappas Capital, CDPQ, Chicago Growth Partners, BB Biotech, CTI Life Sciences, Tekla Capital Management, Innovis Investment Partners
- Series C, Aug 31, 2005, $30M — Enterprise Partners Venture Capital, Forward Ventures, VantagePoint Capital, William Blair Capital Partners, CDIB Capital Group, CDPQ, BB Biotech, Tekla Capital Management, A. M. Pappas & Associates
- Series B, Jan 14, 2004, $30M — Enterprise Partners Venture Capital, Forward Ventures, William Blair Capital Partners, CDIB Capital Group, CDPQ
- Series A, Apr 3, 2002, $10M — Enterprise Partners Venture Capital, Forward Ventures

## Investors

- Enterprise Partners Venture Capital (https://capitalatlas.ai/funds/enterprise-partners-venture-capital) — Series A, Series B, Series C, Series D
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B, Series C, Series D
- William Blair Capital Partners (https://capitalatlas.ai/funds/william-blair-capital-partners) — Series B, Series C, Series D
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series B, Series C
- CDPQ — Series B, Series C, Series D
- VantagePoint Capital (https://capitalatlas.ai/funds/vantagepoint-capital) — Series C, Series D
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series C, Series D
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C, Series D
- A. M. Pappas & Associates — Series C
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series D
- Chicago Growth Partners (https://capitalatlas.ai/funds/chicago-growth-partners) — Series D
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series D
- Innovis Investment Partners — Series D